MiNK Therapeutics shared on LinkedIn: .
“This quarter we made significant strides across our iNKT cell programs, including generating clinical data from our agenT-797 program, strengthening our financial position, and advancing our innovative next-generation therapies.
Read more in our Q1 report.”
Source: MiNK Therapeutics/LinkedIn